Circulating Tumor Cell Device Gets Safer FDA Classification
Published Date: 5/6/2026
Rule
Summary
The FDA is officially classifying the circulating tumor cell enrichment device as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps patients get access to innovative cancer-fighting tools faster and keeps the device safe and effective. The new rules take effect May 6, 2026, and could save time and money for makers and users of this device.
Analyzed Economic Effects
4 provisions identified: 3 benefits, 1 costs, 0 mixed.
Easier Path for Future Devices
FDA states that once this device type is classified into Class II via the De Novo process, it can serve as a predicate for future devices. That means other device sponsors may be able to use the less-burdensome 510(k) process to bring substantially equivalent devices to market instead of submitting a De Novo request or a premarket approval application.
Device Reclassified to Class II
FDA has classified the circulating tumor cell enrichment device as Class II (special controls). This order is effective May 6, 2026 (and the classification was applicable May 24, 2022). FDA says this classification will provide reasonable assurance of safety and effectiveness and will enhance patients' access to innovative devices by reducing regulatory burdens.
Manufacturers Must Meet Special Controls
Circulating tumor cell enrichment devices remain subject to premarket notification under section 510(k) and must meet the special controls codified at 21 CFR 866.6110. Manufacturers must provide specified labeling (including intended use, limitations, and troubleshooting) and design verification and validation data, including analytical and clinical study documentation demonstrating performance, detection limits, precision, recovery, and stability.
Labeling Limits Use; Not Diagnostic
The device's labeling must prominently state that the standalone device is intended only to enrich circulating tumor cells (CTCs) from peripheral blood of previously diagnosed cancer patients and is not intended for diagnostic, prognostic, or monitoring use. Labeling must also state that results do not provide information about a patient's current health and that downstream assays need separate validation.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-09767 — Oscar Bobo: Final Debarment Order
Oscar Bobo is officially banned for 5 years from importing any drugs into the U.S. because he repeatedly brought in mislabeled medicines that don’t follow FDA rules. He ignored the chance to defend himself, so the ban started on May 15, 2026. This means no drug imports from him for a while, but he can apply to end the ban anytime if he meets FDA’s conditions.
2026-09448 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; The Real Cost Campaign Outcomes Evaluation Study: Cohort 3
The FDA is asking for approval to collect info for the third group in its Real Cost Campaign, which teaches kids about the dangers of tobacco. This helps the FDA improve its anti-smoking messages and protect young people’s health. Comments on this info collection are open until June 12, 2026, with no new costs for participants.
2026-09543 — Agency Information Collection Activities; Proposed Collection; Comment Request; Postmarketing Adverse Experience Reporting
The FDA wants your thoughts on how drug companies report problems after their products hit the market. This affects drug makers and healthcare folks who keep track of side effects. They’re asking for comments by July 13, 2026, to help improve the process without adding extra costs or paperwork.
2026-09544 — Modified Risk Tobacco Product Application: Renewal Applications for VLN® King and VLN® Menthol King, Cigarette Products Submitted by 22nd Century Group Inc.
The FDA is inviting the public to comment on the renewal of special approval for two cigarette products by 22nd Century Group Inc. These products claim to lower health risks compared to regular cigarettes. If approved, the renewal keeps these products on the market with their modified risk status, affecting smokers and the tobacco industry starting May 13, 2026.
2026-09335 — Medical Devices; Immunology and Microbiology Devices; Classification of the Device To Detect and Identify Microorganism Nucleic Acids and Resistance Markers From Patients With Suspected Orthopedic Infection
Hey there! This update is all about a new medical device that helps doctors quickly find germs and their resistance traits in people who might have bone infections. It affects hospitals and labs by officially classifying this device, making it easier and faster to diagnose tough infections. The change kicks in soon, helping patients get the right treatment without delay—and it could save money by avoiding wrong meds!
2026-09368 — Enforcement Priorities for Certain New Tobacco Products Marketed Without Premarket Authorization; Guidance for Industry; Availability
The FDA is setting clear rules for certain new tobacco products like e-cigarettes and nicotine pouches that don’t have official approval yet. Companies selling these products without permission might face enforcement actions starting now, so they need to get authorized or risk penalties. This helps protect public health and keeps the market fair and safe.
Previous / Next Documents
Previous: 2026-08811 — Medical Devices; Immunology and Microbiology Devices; Classification of the Device To Preserve and Stabilize Relative Abundances of Microbial Nucleic Acids in Clinical Samples
The FDA is officially putting a special label (Class II) on devices that keep tiny germs’ DNA stable in medical samples. This change makes sure these devices are safe and work well, while also making it easier and faster for new, helpful devices to reach patients. The new rules started May 6, 2026, and could save time and money for companies making these devices.
Next: 2026-08813 — Medical Devices; Ophthalmic Devices; Classification of the Corneal Storage Medium With Preservatives Including Antifungals
The FDA is officially putting corneal storage fluids with preservatives and antifungals into a safer, easier-to-manage category called Class II. This change helps make sure these eye care products are safe and effective while speeding up access to new, helpful devices. Starting May 6, 2026, companies will follow these new rules, which could save time and money by cutting down on red tape.